A study to assess cell therapy as a treatment to prevent kidney transplant rejection. The trial will involve purification of naturally occurring regulatory T cells (nTregs) from living-donor renal transplant recipients. The cells will then be grown in the laboratory and re-infused into the patient five days after the kidney transplant. This trial is part of an international European Union funded consortium aimed at evaluating cellular immunotherapy in solid organ transplantation (The ONE Study). It is anticipated that immune regulation induced by nTreg therapy can eventually be used to recude the need for conventional immunosuppression in transplant recipients.
Decades of immunosuppressive drug development has produced an array of powerful pharmacological agents, but the various drawbacks with these treatments leaves considerable room for improvement. By harnessing the power of suppressive mechanisms in the human immune system, regulatory cell therapy may be able to support peripheral tolerance and induce a level of donor-specific unresponsiveness that allows for a reduction in the use of conventional immunosuppression in organ transplant recipients. Several alternative regulatory cell types have been identified as potential adjunct immunotherapies for solid organ transplantation and are now approaching a stage of development that would allow clinical testing in an early-stage trial. The EU-funded international ONE study consortium aims to answer the question as to whether Treg treatment, or other immunoregulatory cell-based therapies, can be advanced in the clinical management of solid organ transplant recipients. This particular Treg trial aims to explored the potential of Treg therapy as an adjunct immunosuppressive treatment in living-donor renal transplant recipients through a clinical protocol design shared by other investigators in the ONE study group testing additional regulatory cell therapies in seperate trials.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
Guy's Hospital
London, United Kingdom
The Oxford Transplant Centre - Churchill Hospital
Oxford, United Kingdom
Incidence of biopsy-confirmed acute rejection.
Time frame: 60 weeks
Time to first acute rejection episode
Time frame: 60 weeks
Severity of acute rejection episodes
Time frame: 60 weeks
Total immunosuppressive burden
Time frame: 60 weeks
Incidence of chronic graft dysfunction
Time frame: 60 weeks
Incidence of graft loss through rejection
Time frame: 60 weeks
Incidence of adverse drug reactions
Time frame: 60 weeks
Incidence of major and/or opportunistic infections
Time frame: 60 weeks
Incidence of neoplasia.
Time frame: 60 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.